Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Preferred Stock Liabilities: 2015-2016

  • Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities rose 26.50% to $77.0 million in Q4 2016 from the same period last year, while for Dec 2016 it was $77.0 million, marking a year-over-year increase of 26.50%. This contributed to the annual value of $77.0 million for FY2016, which is 26.50% up from last year.
  • Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities amounted to $77.0 million in Q4 2016, which was up 26.50% from $60.9 million recorded in Q4 2015.
  • In the past 5 years, Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities registered a high of $77.0 million during Q4 2016, and its lowest value of $60.9 million during Q4 2015.
  • Its 2-year average for Preferred Stock Liabilities is $68.9 million, with a median of $68.9 million in 2015.
  • Data for Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities shows a peak YoY increased of 26.50% (in 2016) over the last 5 years.
  • Quarterly analysis of 2 years shows Viridian Therapeutics, Inc.\DE's Preferred Stock Liabilities stood at $60.9 million in 2015, then increased by 26.50% to $77.0 million in 2016.